CGRP 8-37 Enhances Lipopolysaccharide-induced Acute Lung Injury and Regulating Aquaporin 1 and 5 Expressions in Rats
Overview
Physiology
Affiliations
Calcitonin gene-related peptide (CGRP) has been shown to play important roles in biological functions. However, there is very little evidence on the value of CGRP in lipopolysaccharide (LPS)-induced acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Therefore, this study aimed to investigate the role of CGRP in LPS-induced ALI in rats. In the experiment, Sprague-Dawley (SD) rats were randomized into control, an antagonist of α-calcitonin gene-related peptide receptor (CGRP8-37), LPS groups, and CGRP8-37 + LPS groups. ALI model was prepared through retrograde injection of LPS (10 mg/kg). At 6 and 12 h, bronchoalveolar lavage was performed and used to assess total cell count and levels of tumor necrosis factor-α, interleukin-1β, -6, and -10 by enzyme-linked immunosorbent assay (ELISA). Lung tissue was collected for assessing wet-to-dry (W/D) ratio, hematoxylin and eosin staining. Aquaporin (AQP)-1 and -5 expressions in lung tissues were detected by quantitative PCR and Western blot. The results showed that histological injury, total cell count, and W/D ratio significantly reduced in LPS group after 6 h. The levels of inflammatory cytokines in CGRP8-37 + LPS-treated rats were higher than that in LPS-treated rats (all, P < 0.001). Real-time RT-PCR analysis showed that levels of AQP-1 in rats from CGRP8-37 + LPS group was lower than that in LPS-treated rats (P = 0.005 and P < 0.001). Western blotting analysis showed that AQP-1 protein levels at 6 h significantly decreased in CGRP8-37 + LPS rats. Together, our data suggest that CGRP antagonists, CGRP8-37 could enhance ALI induced by LPS in the rat model, and regulate the expression levels of AQP-1 and AQP-5 by affecting inflammatory cytokines. Thereby, regulating endogenous CGRP may be a potential treatment for ALI/ARDS.
Exploring Aquaporins in Human Studies: Mechanisms and Therapeutic Potential in Critical Illness.
Vrettou C, Issaris V, Kokkoris S, Poupouzas G, Keskinidou C, Lotsios N Life (Basel). 2025; 14(12.
PMID: 39768394 PMC: 11676363. DOI: 10.3390/life14121688.
Aquaporins in sepsis- an update.
Rump K, Adamzik M Front Immunol. 2024; 15:1495206.
PMID: 39544938 PMC: 11560437. DOI: 10.3389/fimmu.2024.1495206.
Yamashita A, Ito Y, Osada M, Matsuda H, Hosono K, Tsujikawa K Int J Mol Sci. 2024; 25(18).
PMID: 39337592 PMC: 11432488. DOI: 10.3390/ijms251810107.
Potential pharmaceuticals targeting neuroimmune interactions in treating acute lung injury.
Wu D, Liao X, Gao J, Gao Y, Li Q, Gao W Clin Transl Med. 2024; 14(8):e1808.
PMID: 39129233 PMC: 11317502. DOI: 10.1002/ctm2.1808.
Aquaporins: Potential Targets in Inflammatory Diseases.
Bozkurt A, Halici H, Yayla M Eurasian J Med. 2024; 55(1):106-113.
PMID: 39128069 PMC: 11075024. DOI: 10.5152/eurasianjmed.2023.23357.